ATLASATLAS fair value
ATLAS has no fair value for this stock today.
20/20 Biolabs (AIDX)
20/20 Biolabs stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NASDAQ
$0.23▲ +0.47%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on 20/20 Biolabs in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On 20/20 Biolabs
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives 20/20 Biolabs a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.19 and $0.26; in 9 out of 10, between $0.15 and $0.34. Estimated annual volatility is 81%.
Key numbers
- Revenue (12 months)
- $2.0M
- Revenue growth (YoY)
- +16.7%
- Gross margin
- 29.6%
- Operating margin
- -162.9%
- Net margin
- -182.8%
- Return on equity
- -331.2%
- Free cash flow (12 months)
- $-0.8M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for AIDX right now, but it does show its odds of rising: close to a coin flip.
On the business: revenue grew 16.7% year over year; net margin is 182.8%.
Its beta is 0.00: it tends to move less than the market.
About the company
20/20 Biolabs, Inc. is a commercial-stage diagnostics company focused on AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
Want to see everything about 20/20 Biolabs?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does 20/20 Biolabs do?
20/20 Biolabs, Inc. is a commercial-stage diagnostics company focused on AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
What is the chance AIDX goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, AIDX ends the month between $0.19 and $0.26.
How volatile is AIDX?
ATLAS estimates annual volatility at 81%. In a typical month, half of the outcomes end between $0.19 and $0.26.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer